Market Segmentation

By Diagnostic Purpose

• Screening
• Blood donor screening
• Antenatal (pregnancy) screening
• Community / population screening
• Occupational screening (healthcare workers)
• Diagnosis / Confirmation
• Acute HBV diagnosis
• Chronic HBV diagnosis
• Differentiation from other hepatitis causes
• Disease Monitoring
• Viral load monitoring during treatment
• Treatment response monitoring
• Liver disease progression risk assessment (with HBV markers)
• Others

By Biomarker / Test Target (HBV markers)

• HBsAg (screening/diagnosis)
• Anti-HBs (immunity / vaccine response)
• Total Anti-HBc (past or current infection)
• IgM Anti-HBc (acute/recent infection)
• HBeAg
• Others

By Test Modality / Technology

• Immunoassays (Serology)
• Rapid Diagnostic Tests (RDTs)
• ELISA / EIA
• CLIA / ECLIA
• Chemiluminescent microparticle immunoassay (CMIA) (platform-based)
• Others
• Molecular / Nucleic Acid Testing (NAT)
• Real-time PCR (qPCR) (quantitative viral load)
• Digital PCR (niche/advanced)
• Isothermal amplification (e.g., LAMP)
• Others
• C) Sequencing & Advanced Methods)
• Sanger sequencing
• Next-Generation Sequencing (NGS)
• Multiplex molecular panels (HBV + HCV + HIV, etc.)

By Product Type

• Instruments / Analyzers
• Immunoassay analyzers
• Molecular platforms (PCR/NAT systems)
• Reagents & Kits
• Serology reagent kits
• HBV DNA quantification kits
• Genotyping/resistance kits
• Consumables
• Cartridges, assay strips, tubes, tips, extraction kits
• Software / Informatics
• Viral load analysis/reporting modules
• LIS integration, QC analytics

By Sample Type

• Whole blood
• Serum
• Plasma
• Dried blood spot (DBS)
• Others

By End User / Testing Site

• Hospitals & hospital laboratories
• Independent / private diagnostic laboratories
• Blood banks / transfusion centers
• Public health laboratories
• Clinics & primary care centers
• Research institutes / academic labs
• Others

By Patient / Risk Group

• Pregnant women
• Newborns/infants
• General adult population 
• Healthcare workers
• Hemodialysis patients
• Immunocompromised patients
• People living with HIV
• Household/sexual contacts of HBV-positive individuals
• Migrants from high-prevalence regions
• Others